September 22, 2022 AlzeCure presents new data on the anti-inflammatory effects of its TrkA-NAM pain project at IASP 2022
September 16, 2022 AlzeCure’s Alzheimer’s project NeuroRestore ACD856 shows positive effect on brain activity in clinical trial
August 30, 2022 AlzeCure gets abstract accepted on potential neuroprotective effects of NeuroRestore ACD856
August 16, 2022 New review article on AlzeCure’s NeuroRestore as a novel Alzheimer’s therapy published in Drug Discovery Today
August 2, 2022 AlzeCure presents new clinical data with NeuroRestore ACD856 at the Alzheimer’s conference AAIC
July 5, 2022 AlzeCure gets abstract on new clinical study data with NeuroRestore accepted at the Alzheimer’s conference AAIC
June 29, 2022 Positive data from the clinical phase I MAD study with AlzeCure’s Alzheimer’s project NeuroRestore ACD856
June 21, 2022 First patient included in AlzeCure’s Phase II clinical trial in neuropathic pain with non-opioid ACD440
June 15, 2022 Study plan of AlzeCure’s Phase II clinical study in neuropathic pain with non-opioid ACD440 now available
May 25, 2022 AlzeCure gets approval to start Phase II clinical trial with non-opioid pain project ACD440
May 10, 2022 AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference
April 13, 2022 AlzeCure’s rights issue is registered and the trading in Paid Subscription Shares ceases
April 11, 2022 AlzeCure carries out a set-off issue in connection with ACD440 entering phase II and Acturum Life investing in the company
March 17, 2022 AlzeCure presents new data at AD/PD meeting on NeuroRestore’s positive effect on mitochondrial function
March 8, 2022 AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease
February 8, 2022 AlzeCure is moving towards Phase IIa clinical trial with ACD440 based on guiding response from the FDA
January 27, 2022 Novel data in Alzstatin Alzheimer’s project presented at the 11th Pharmaceutical Profiling meeting
January 18, 2022 AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conference
January 11, 2022 AlzeCure gets late breaking abstract accepted on NeuroRestore’s positive effect on mitochondrial function
